The authors concluded that intermittent low-dose teriparatide reduced vertebral and non-vertebral fractures and increased mineral bone density in postmenopausal women, but further long-term safety research was required. The authors' conclusions appeared to reflect the results, but small sample sizes for some comparisons and unknown study quality made it difficult to assess their reliability.
Study selection
Randomised controlled trials (RCTs) that evaluated the effect of teriparatide on bone mineral density and fractures in women with a natural or surgically-induced menopause and osteoporosis were eligible for inclusion. Studies could compare teriparatide with placebo, hormone replacement therapy, biphosphonates, calcitonin or calcium plus vitamin D. Studies had to assess bone mineral density using DEXA (dual-energy x-ray absorptiometry) and/or QCT (quantitative computed tomography) and report the number of vertebral and non-vertebral fractures and toxicity (including treatment withdrawals due to adverse events).
The included studies compared the following agents: subcutaneous teriparatide (20μg and 40μg) versus placebo; subcutaneous teriparatide (40μg) versus oral alendronate (10μg); teriparatide (400 units or 25μg) plus oestrogen versus oestrogen; and teriparatide (500 units or 40μg) plus nafarelin acetate versus nafarelin acetate. Participants included women with previous non-traumatic fractures, bone mineral density at least 1 or 2.5 standard deviations below the mean and women with endometriosis. Duration of follow-up ranged from six to 36 months.
Two reviewers independently selected studies.
Assessment of study quality
Two reviewers independently assessed validity using the Jadad criteria (randomisation, blinding and reporting of withdrawals).
Data extraction
Dichotomous data were reported as relative risks with 95% confidence intervals (CI); weighted mean differences were used for continuous data. Two reviewers extracted data. Differences were resolved with the help of a third reviewer.
Methods of synthesis
The authors stated that they planned to conduct sensitivity analyses, but no meta-analyses were presented. The studies were grouped by comparator and combined in narrative synthesis.
Results of the review
Four RCTs were included (n=1,867). Teriparatide was associated with a statistically significant increase in whole-body bone mineral density (relative risk 3.1, 95% CI: 1.65 to 4.55 with 20μg and relative risk 4.5, 95% CI: 2.78 to 6.22 with 40μg), lumbar bone mineral density (relative risk 9.6, 95% CI: 7.79 to 9.41 with 20μg and relative risk 12.6, 95% CI: 11.62 to 13.58 with 40μg) and femoral bone mineral density (relative risk 3.6, 95% CI: 2.75 to 4.45 with 20μg and relative risk 4.6, 95% CI: 3.71 to 5.49 with 40μg).
There was no significant difference between teriparatide 20μg and 40μg in whole-body bone mineral density, femoral bone mineral density and rates of treatment withdrawal. Treatment withdrawal was significantly higher with teriparatide 40μg compared to placebo and with teriparatide 40μg compared to 20μg. Headache, nausea cramps, hypercalcaemia and the formation of anti-PTH (parathyroid hormone) antibodies were significantly more common in the teriparatide treatment groups.
Teriparatide versus alendronate (one RCT, n=146):
There was no significant difference between teriparatide and alendronate in the rate of new vertebral or non-vertebral fractures. Teriparatide was associated with an increase in whole-body and lumbar column and femur bone mineral density (results data and the statistical significance of this increase were not reported). The following adverse events were more common in the teriparatide treatment group: cramps; elevated serum and urinary calcium. Alendronate was associated with an increase risk of worsening lumbar pain.
Teriparatide plus oestrogen versus oestrogen (one RCT, n=34): Teriparatide plus oestrogen was associated with significant reduction in new vertebral fractures (relative risk 0.15, 95% CI: 0.03 to 0.73).
Teriparatide plus nafarelin versus nafarelin (one RCT, n=50): Bone mass increased by 3.4% in the teriparatide plus nafarelin group and by 3.5% in the nafarelin only group.
Cost information
The authors reported that teriparatide costs US$14,000 dollars for two years.
